Transition Bio key facts
- Operator of a biotechnology company intended to build a hypothesis-free drug discovery and diagnostics platform for human health care advancement.
- Transition Bio’s last known valuation is $26.8M.
- It has raised $76.5M across 3 recorded rounds; the latest was Early Stage VC ($13.3M) in Oct 2024.
- Notable investors include Bristol-Myers Squibb, Lifeforce Capital, Magnetic Ventures, Northpond Ventures, Taiho Ventures — 6 tracked in total.
- Transition Bio has filed 4 Form Ds with the SEC since 2022, most recently Oct 2024 ($13.3M sold to 8 investors).
- Status: Privately Held (backing).
- ·Watch Transition Bio: the Monday email on marks, rounds and moves
Transition Bio funding rounds
3 roundsTransition Bio valuation
Transition Bio's last known valuation is $26.8 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
How much has Transition Bio raised?
Transition Bio has raised $76.5 million across 3 recorded rounds since 2022. The largest was a $6 million early-stage round in Dec 2023; the most recent was a $13.3 million early-stage round in Oct 2024.
Transition Bio has filed 4 Form Ds with the SEC since 2022, most recently in Oct 2024 ($13.3 million sold to 8 investors).
Transition Bio investors
6 investors are on record for Transition Bio, including Bristol-Myers Squibb, Lifeforce Capital, Magnetic Ventures and Northpond Ventures. The early-stage round in Oct 2024 drew 8 investors.
About Transition Bio
Operator of a biotechnology company intended to build a hypothesis-free drug discovery and diagnostics platform for human health care advancement. The company harnesses droplet microfluidic approaches and protein biophysics platforms to characterize condensates with unprecedented precision, enabling medical practitioners to map condensates in molecular detail.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2020
- Employees
- 27
- Website
- transitionbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Transition Bio’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.